ONCOLOGY

Meta-analysis finds risk significantly elevated only with use for more than a year.

Exploratory analyses identify potential biomarkers.

Final OS analysis of the phase 3 double-blind ARAMIS study.

Significant OS improvement was reported vs upfront surgery in UTUC.

Secondary analysis of randomized trial supports NCCN recommendations.

Final OS analysis of phase 3 double-blind SPARTAN study.

Nivolumab plus ipilimumab improves survival irrespective of PD-L1 expression.

Safer procedure with advances in robotic surgery may have contributed to increasing trend.

Avelumab with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma

Retrospective study reported similar pathologic and long-term oncologic outcomes.

Recommendations for routine use in NSCLC, cholangiocarcinoma, prostate, and ovarian cancers.

Some men can have longer follow-ups.

The appeal period for this appraisal will close at 5 pm on Friday 11 September 2020

Additional follow-up data from phase 3 CA184-043 study.